Who are fluticasone/salmeterol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Symbicort® forte Turbohaler®, Symbicort 160/4.5 pMDI, Foster BDP/Formoterol, Budesonide-Formoterol treatment, Symbicort Turbuhaler 160/4.5, Drug: Budesonide/formoterol (Symbicort Turbuhaler.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fluticasone-salmeterol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

fluticasone/salmeterol — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

fluticasone/salmeterol (fluticasone/salmeterol) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA). Area: Respiratory/Pulmonology.

marketed Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol) Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

fluticasone/salmeterol (fluticasone/salmeterol) — Hull University Teaching Hospitals NHS Trust. Fluticasone/salmeterol combines a corticosteroid that reduces airway inflammation with a long-acting beta-2 agonist that relaxes airway smooth muscle.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
fluticasone/salmeterol TARGET	fluticasone/salmeterol	Hull University Teaching Hospitals NHS Trust	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA)	Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)
Symbicort® forte Turbohaler®	Symbicort® forte Turbohaler®	University Hospital, Antwerp	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA)	Glucocorticoid receptor (budesonide); beta-2 adrenergic receptor (formoterol)
Symbicort 160/4.5 pMDI	Symbicort 160/4.5 pMDI	Allergy and Asthma Center of El Paso	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA)	Glucocorticoid receptor (budesonide); beta-2 adrenergic receptor (formoterol)
Foster BDP/Formoterol	Foster BDP/Formoterol	Chiesi Farmaceutici S.p.A.	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA)	Glucocorticoid receptor (beclomethasone); beta-2 adrenergic receptor (formoterol)
Budesonide-Formoterol treatment	Budesonide-Formoterol treatment	AstraZeneca	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA)	Glucocorticoid receptor (budesonide); beta-2 adrenergic receptor (formoterol)
Symbicort Turbuhaler 160/4.5	Symbicort Turbuhaler 160/4.5	AstraZeneca	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA)	Glucocorticoid receptor (budesonide); beta-2 adrenergic receptor (formoterol)
Drug: Budesonide/formoterol (Symbicort Turbuhaler	Drug: Budesonide/formoterol (Symbicort Turbuhaler	AstraZeneca	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA)	Glucocorticoid receptor (budesonide); beta-2 adrenergic receptor (formoterol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) class)

Chiesi Farmaceutici S.p.A. · 5 drugs in this class
AstraZeneca · 5 drugs in this class
Mundipharma Research Limited · 4 drugs in this class
GlaxoSmithKline · 2 drugs in this class
Milton S. Hershey Medical Center · 1 drug in this class
Mundipharma Korea Ltd · 1 drug in this class
SkyePharma AG · 1 drug in this class
Actavis Inc. · 1 drug in this class
University Hospital, Antwerp · 1 drug in this class
Allergy and Asthma Center of El Paso · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). fluticasone/salmeterol — Competitive Intelligence Brief. https://druglandscape.com/ci/fluticasone-salmeterol. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing